PHARMAIN CORPORATION

Basic Information

19805 N. Creek Pkwy, Suite 200
Bothell, WA, 98011-8251

http://www.pharmain.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 167580682
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 5


  1. Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Female sexual arousal disorder (FSAD), one of the conditions commonly described as Female sexual dysfunction (FSD) is common among older women and can be a signifi ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Medical countermeasure after radiation exposure

    Amount: $599,687.00

    DESCRIPTION (provided by applicant): New treatments for radiation injury to the GI-tract are desperately needed to ensure survival after exposure to ionizing radiation arising from accident, nuclear w ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Subcutaneous Drug Development for Portal Hypertension Ascites

    Amount: $573,585.00

    DESCRIPTION (provided by applicant): The prevalence of all types of ascites, irrespective of the cause, is 41.7 in 100,000 with 80% of these due to cirrhosis. Ascites is treated with a salt restricted ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. EGF/Gastrin for Islet Regeneration

    Amount: $1,543,646.00

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. Nanocarrier formulated enzyme for the treatment of S. aureus infection

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infe ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Vasoactive intestinal peptide for the treatment of psoriasis

    Amount: $372,133.00

    DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory skin disease that to this date is only insufficiently controlled by currently available treatments which can also come with sev ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases

    Amount: $599,949.00

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Nanocarrier-formulated anti-fibrotic peptides for cirrhosis- Fast Track SBIR

    Amount: $782,928.00

    DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the ...

    SBIR Phase II 2010 Department of Health and Human Services
  9. Outpatient treatment for portal hypertension

    Amount: $223,422.00

    DESCRIPTION (provided by applicant): Portal hypertension (increased pressure in the portal venous system) is one of the main consequences of cirrhosis. Although the reduction of portal hypertension is ...

    SBIR Phase I 2010 Department of Health and Human Services
  10. Nanocarrier-formulated anti-fibrotic peptides for cirrhosis- Fast Track SBIR

    Amount: $160,363.00

    DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government